Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Imperial College London
Headquarters: London, United Kingdom
Website: http://www3.imperial.ac.uk
Year Founded: 1907
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Dec 13, 2023
Emerging Company Profile
Myricx: ADCs with a lipidation inhibitor payload
U.K.-based Myricx is turning a small molecule for parasitic diseases into an ADC payload for cancers
BioCentury | Aug 25, 2023
Discovery & Translation
Denali’s brain delivery method; plus CAR T cell therapy combo and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 1, 2023
Emerging Company Profile
Gensaic: redosable, large-capacity gene therapies
MIT spinout harnessing the human phageome to develop gene delivery vehicles that solve the problems of AAVs
BioCentury | Dec 6, 2022
Product Development
Dec. 5 Quick Takes: Nkarta reports 70% complete response
Plus: Verve falls on clinical hold and updates from J&J, Affinia, TherapeuticsMD, Biogen and more
BioCentury | Oct 31, 2022
Discovery & Translation
Maze identifies two regulators of ALS target ATXN2; plus updates from Black Diamond and more
BioCentury’s roundup of translational news
BioCentury | Jun 20, 2022
Deals
U.K. partners to accelerate gene therapy development for dementia
CGT Catapult, UK DRI to work with academic centers to identify assets
BioCentury | Oct 6, 2021
Product Development
WHO green light for GSK malaria vaccine culminates 30 years of R&D
First vaccine against human parasitic disease could save 22,000 lives per year
BioCentury | Jul 30, 2021
Distillery Therapeutics
Inhibiting RPS6KA6 with floxacin antibiotics for bladder, lung cancers
DISEASE CATEGORY: Cancer
INDICATION: Bladder cancer; lung cancer Derivatives of the antibiotics moxifloxacin and trovafloxacin and other inhibitors of RPS6KA6 could treat bladder and lung
INDICATION: Bladder cancer; lung cancer Derivatives of the antibiotics moxifloxacin and trovafloxacin and other inhibitors of RPS6KA6 could treat bladder and lung
Items per page:
1 - 10 of 195